KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dynavax Technologies (DVAX) Research & Development: 2009-2025

Historic Research & Development for Dynavax Technologies (DVAX) over the last 17 years, with Sep 2025 value amounting to $19.1 million.

  • Dynavax Technologies' Research & Development rose 32.72% to $19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.8 million, marking a year-over-year increase of 29.44%. This contributed to the annual value of $61.5 million for FY2024, which is 12.14% up from last year.
  • As of Q3 2025, Dynavax Technologies' Research & Development stood at $19.1 million, which was up 15.02% from $16.6 million recorded in Q2 2025.
  • In the past 5 years, Dynavax Technologies' Research & Development registered a high of $19.4 million during Q1 2025, and its lowest value of $6.2 million during Q3 2021.
  • For the 3-year period, Dynavax Technologies' Research & Development averaged around $15.6 million, with its median value being $14.4 million (2024).
  • As far as peak fluctuations go, Dynavax Technologies' Research & Development decreased by 27.40% in 2021, and later skyrocketed by 109.54% in 2022.
  • Over the past 5 years, Dynavax Technologies' Research & Development (Quarterly) stood at $11.1 million in 2021, then grew by 15.62% to $12.9 million in 2022, then rose by 9.84% to $14.1 million in 2023, then soared by 32.23% to $18.7 million in 2024, then skyrocketed by 32.72% to $19.1 million in 2025.
  • Its Research & Development was $19.1 million in Q3 2025, compared to $16.6 million in Q2 2025 and $19.4 million in Q1 2025.